Navigation Links
PAREXEL Expands Global Clinical Pharmacology Capabilities

BOSTON, March 31 /PRNewswire-FirstCall/ -- PAREXEL International Corporation (Nasdaq: PRXL), a leading global biopharmaceutical services provider, today announced that the Company had completed the expansion of three Clinical Pharmacology Research Units located in Baltimore, Maryland in the United States; London, United Kingdom; and Berlin, Germany in order to meet growing client demand for expertise-based studies in the early phases of clinical development.

"Continued expansion of local capabilities combined with an integrated global clinical pharmacology presence has been a cornerstone of PAREXEL's leadership in early clinical development. As biopharmaceutical companies have been conducting more Phase I and Proof of Concept studies with increasing complexity, PAREXEL has been well positioned to meet their needs. In this regard, we are a top provider of expertise-based Phase I services and have more than 550 beds, which is among the largest capacities worldwide," said Herman Scholtz, M.D., Head of International Clinical Pharmacology, PAREXEL. "Clients rely on our in-depth medical and therapeutic expertise to help them conduct rigorous clinical trials in order to identify and select promising new compounds." Dr. Scholtz added, "Long before hospital-based units became an industry best practice, PAREXEL saw the benefit of that approach and located our clinical pharmacology research units in hospitals in order to provide a safe, high-quality environment for early phase development activities."

In Baltimore, PAREXEL's Clinical Pharmacology Research Unit has been expanding capabilities and capacity for client programs since 2001, when the unit opened. With its most recent expansion, the unit now has 90 beds, representing the largest such facility in the region. The unit has deep specialization in many clinical areas such as vaccine and immunology, pulmonary, and oncology studies, and provides leading offerings such as advanced neuroimaging and radiochemistry capabilities using Positron Emission Tomography (PET).

The PAREXEL Clinical Pharmacology Research Unit in London, established more than 15 years ago, has been expanded to a 64-bed capacity. The unit has experience with all types of Phase I studies, including pharmacokinetic and pharmacodynamic studies, and has the ability to conduct PET studies, as well. Clinical pharmacology experts based in the London unit have experience across a broad range of therapeutic areas, with extensive expertise in conducting cardiology and respiratory studies. The unit has a dedicated respiratory laboratory, and is outfitted with cardiac telemetry and electrocardiogram (ECG) monitoring.

PAREXEL has two long-established Clinical Pharmacology Research Units in Berlin. With the recent expansion, the units now have 160 total beds. The two sites have dedicated medical teams that utilize identical equipment and systems to assure harmonized procedures and workflow. The units have sleep research capabilities and a sleep laboratory, as well as extensive expertise in cardiovascular, central nervous system, respiratory, dermatology, metabolism and endocrine, and infectious disease studies.

In addition to the units noted above, PAREXEL also has clinical pharmacology research units in San Diego and Los Angeles in the United States, and in Bloemfontein and George, South Africa. PAREXEL also provides early clinical development programs through a joint venture arrangement with Synchron Research based in India. The Company's northern and southern hemisphere locations provide seasonal benefits for year-round studies, as well as access to specialized patient populations and the ability to conduct multi- site studies for parallel clinical development. All of the research units are equipped with advanced, state-of-the-art technologies, and utilize PAREXEL's proprietary ClinBase(TM) technology, an electronic data capture and information management system that is fully validated and 21CFR part 11- compliant.

PAREXEL's clinical pharmacology experts, including Board Certified medical doctors, have a broad range of therapeutic experience, including the central nervous system, cardiovascular, respiratory, metabolism/ endocrine, and oncology fields. PAREXEL's Clinical Pharmacology Research Units provide bioanalytical services, data management, biostatistics, medical writing, pharmacokinetic services, as well as consulting services for early phase clinical studies.

About PAREXEL International

PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 64 locations throughout 51 countries around the world, and has more than 7,300 employees. For more information about PAREXEL International visit

This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the period ended December 31, 2007 as filed with the SEC on February 7, 2008, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL and ClinBase are registered trademarks of PAREXEL International Corporation, and PERCEPTIVE INFORMATICS is a registered trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective business and are hereby acknowledged.


Jennifer Baird, Director of Public Relations Rebecca Passo

PAREXEL International SHIFT Communications

Tel: +781-434-4409 Tel: +617-779-1817

Email: Email:

SOURCE PAREXEL International Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
2. Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkins Lymphoma
3. VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome
4. Cellectar Expands Clinical Management Team
5. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
6. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
7. Progen Announces Commencement of Global Phase 3 Study for PI-88 in Post- Resection Liver Cancer
8. Gates Foundation Seeks Proposals for Innovative Global Health Research
9. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
10. Dr. Rajeev Venkayya Joins Gates Foundation as Director of Global Health Delivery
11. IBA and Elekta Initiate Global Particle Therapy Program at ASTRO
Post Your Comments:
(Date:11/25/2015)... Nov. 26, 2015  The total global healthcare industry is ... 2015-2016. Latin America has the highest ... (excluding Japan ), is second with growth ... to face increased healthcare expenditure. In 2013-2014, total government funded ... 43.5% in 2008-2009 to 41.2% in 2013-2014. In real terms, ...
(Date:11/25/2015)... Nov. 25, 2015  The American Academy of ... (ACOG), and the March of Dimes cheered today,s ... Our Infants Act of 2015 (S.799), which ... newborns born exposed to drugs, such as opioids, ... introduction, all three organizations have worked together leading ...
(Date:11/25/2015)... AAIPharma Services Corp./Cambridge Major Laboratories, Inc. ... $15.8  Million to expand its laboratories and global ... The expansion will provide additional office space and ... of the pharmaceutical and biotechnology markets. ... up to 40,000 square feet of expanded development ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... ... sauna parts and accessories. , Sauna accessories help improve the bather experience in ... personality. From basic styles for the purist looking for simplicity in design to ...
(Date:11/25/2015)... ... ... According to an article published November 10th by The Missoulian, ... a breakthrough for performing hernia repairs. The article explains that the biggest advantage that ... can greatly reduce the pain that a patient might otherwise experience after a surgical ...
(Date:11/25/2015)... ... November 25, 2015 , ... The McHenry County law ... successful appellate decision obtained by Attorneys Francisco J. Botto and Alex C. Wimmer. Attorneys ... Workers’ Compensation Comm’n, 2015 IL App (2d) 130884WC. , According to court documents, Adcock ...
(Date:11/25/2015)... ... 25, 2015 , ... Brillianteen, McGaw YMCA’s student-produced musical show, ... 65th Anniversary Brillianteen Revue, scheduled for March 4-6, 2016. Auditions for this final ... has been a treasured tradition for numerous families in the Evanston community. Over ...
(Date:11/25/2015)... ... November 25, 2015 , ... In honor of Pulmonary Hypertension ... and groups responsible for advancing care for pulmonary hypertension (PH) patients and helping ... public, will receive special recognition throughout 2016 as part of PHA’s 25th anniversary ...
Breaking Medicine News(10 mins):